A protein called PVRL4 has a central role in a number of cancers that originate in epithelial tissue, and anti-PVRL4 antibodies could be used to treat some of these cancers.

Mutagenesis studies identified an androgen receptor mutation that converts enzalutamide-a drug recently approved for the treatment of advanced prostate cancer-into an androgen receptor agonist, and modeling studies informed the design of novel drugs that are effective against the mutant receptor.

By using immune cells called dendritic cells to deliver drugs, it is possible to target and kill specific members of another class of immune cell, known as T cells, and to prevent these cells from attacking the body's own tissues in cases of autoimmune disease.

A bacterial protein can be programmed with short RNA molecules to stimulate genome editing at specific sites in human cells.

Cleavage of a membrane-bound transcription factor by the chemotherapeutic reagent doxorubicin can block the proliferation of tumor cells.

A mathematical model based on enzyme kinetics shows how the relationships between life expectancy, survival rates for children and adults, and national income change over time.